| Comment | 13.840 | Hugh Cleland, CFA | As it looked at this in the last couple of months, but likes their Alzheimer's drug. Pure biotech, where they're burning money every quarter is not easy for him. | 2007-09-07 | |
| BUY | 1.690 | Hugh Cleland, CFA | In general, he does not like Biotech's but he likes this company a lot. Looking at introducing therapy into the Alzheimer's stage, which would be disease altering, which would reverse the effects. Have good US partners. Likes for the long term. | 2007-05-24 | |
| BUY on WEAKNESS | 1.650 | Hugh Cleland, CFA | In diabetes and Alzheimer therapies. Alzheimer is a disease-altering drug, not just the symptoms. Could be 5 to 10 years. If you can, trade around the volatility. Excellent long-term upside. | 2007-03-26 | |
| BUY | 1.750 | Hugh Cleland, CFA | In diabetes, but their big upside now is in their Alzheimer’s work. Their therapy is the only one that could be disease changing, not just the symptoms. It will take 5-7 years to prove it out. | 2007-01-24 | |
| STRONG BUY | 1.520 | Hugh Cleland, CFA | Generally stays away from pure biotech. Interesting diabetes play, but likes it for the Alzheimer’s play. Has a drug that could be disease altering as opposed to symptom altering. It’ll be years before it comes through as a drug, but if it does, sales will be massive. | 2006-12-14 | |
| HOLD | 0.680 | Peter Hodson | Wouldn't be the best company in the biotechnology space. Not a bad company. | 2006-03-27 | |
| BUY | 1.020 | Glenn Paradis, BA, CFA | Has been consolidating around the $1 for some time. Seeing some selling pressures re: warrants that were converted. A relatively high risk name, but if they are successful across one or two of the different platforms they have, stock could be significantly higher. Good management team. | 2005-01-13 | |
| BUY | 1.080 | Peter Hodson | Likes the company. Even though it hasn't done a whole lot, it's starting to form a pretty good base. Now that the sector is a little bit better than it was, it is pretty ownable now. | 2004-12-20 | |
| BUY | 1.030 | Hugh McCauley | Has a few products, but has one primary product in diabetes. If he gets it right, and the animal studies come through in humans, thinks the stock will go from $1 to over $10. The good news is that it has 2/3 other products coming up behind it, so if it drops, will only go down to $0.50. | 2004-12-02 | |
| BUY | 1.020 | Mark Jackson, CFA | Best to own a basket when owing smaller bio techs. Gigh risk/high return. Their diabetes drug, if it flows through, has a huge market potential. News flow has been fairly good. Still early stage. Good management. | 2004-10-04 | |
| BUY on WEAKNESS | 1.030 | Peter Hodson | A pretty decent company. Got smeared with the same brush as Conjuchem. Doesn't expect anything this year as it will probably be sold as a tax loss. OK for the long term. | 2004-09-24 | |
| BUY on WEAKNESS | 0.930 | Werner Muehelemann | Very solid management. A phase 2 drug. Overvalued considering the biotech market has dropped so much. Would be more interesting at $.80/$.90. | 2004-08-09 | |
| TOP PICK | 1.060 | Ed Ho | Biotech world has had a tough time in the last month. This company is progressing well. Will take over the clinical development which is very lucrative for the company. Likes management and their pipeline. | 2004-07-30 | |
| TOP PICK | 1.650 | Ed Ho | Has an interesting pipeline of products. An early stage product is a diabetes treatment. | 2004-06-21 | |
| BUY | 1.120 | Hugh McCauley | Have the best animal model data that he has ever seen. If they can make the transition to human models, the stock would go to $10. Results could be out by the end of this year or the beginning of next. | 2004-05-13 | |
| TOP PICK | 1.030 | Hugh McCauley | A speculative pick. They are going after diabetes, one of the biggest health problems in the world. So far, test have only been done with mice but success has been good. Risky, so don't invest too much. High risk/high reward. | 2004-04-19 | |
| WEAK BUY | 0.820 | Ed Ho | Have some early-stage products which makes it a cheap company. A higher risk name. Good management. | 2004-03-24 | |
Experts that have talked about Transition Therapeutics Inc
Rss Top Picks Feed